With Orphan Drug Designation for POLB 001 now secured, Poolbeg Pharma PLC (AIM:POLB) has entered a more decisive phase.
But it is not just because of the regulatory milestone. It is also because the company is now funded through to key clinical data, allowing it to fully pursue the potential of what Shore Capital sees as a high-value, first-in-class asset.
Earlier this month, Poolbeg raised £4 million to support the development of its pipeline.
That funding has become more significant in context. Shore Capital believes it ensures POLB 001 can progress through phase IIa trials without delay, with data from a first-in-human study in multiple myeloma patients expected in the first half of next year.
For investors, that creates a direct path to the clinical evidence needed to attract a commercial partner and begin to unlock value.
The investment case is beginning to fall into place
Cytokine release syndrome remains one of the most serious constraints on the use of T-cell therapies such as CAR-T and bispecific antibodies.
It can affect more than 70% of patients, triggering severe immune reactions that require treatment in specialist centres. POLB 001, an oral preventative, is designed to reduce this risk and enable broader delivery of immunotherapies in outpatient settings.
There are no approved preventative treatments for CRS.
The US orphan designation now strengthens the case. If approved, POLB 001 would be eligible for seven years of market exclusivity, alongside tax credits and waived regulatory fees.
Combined with a growing patent estate, Shore Capital believes Poolbeg has a significantly stronger hand as it looks to secure a development partner. Exclusivity protections are rarely overturned and are expected to complement the intellectual property already in place.
Execution fully funded
The recent placing provides the financial headroom to reach the next set of value-inflexion points. POLB 001 is expected to enter phase IIa trials later this year, while the company’s oral GLP-1 programme, targeting diabetes and obesity, is also expected to generate early clinical data in 2025.
Both are now fully funded through their next major milestones.
This is central to Poolbeg’s model. The business is designed to generate early clinical proof before seeking commercial partnerships. The absence of near-term funding risk supports a cleaner negotiation with potential partners and should improve the company’s position on valuation.
Market value yet to catch up
Despite these steps forward, the shares continue to trade at a level that Shore Capital believes does not reflect the programme’s commercial potential. The broker sees peak sales for POLB 001 exceeding $5 billion if it delivers on its promise as the first effective preventative treatment for CRS.
The foundations are now in place. Poolbeg has regulatory support, a stronger IP position, and the funding to deliver pivotal data. The next challenge is execution, and with it, the opportunity to transform the company’s valuation.
In afternoon trading, the shares were up 23% at 3.09p.